Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVONASDAQ:CLRBNASDAQ:PRPHNASDAQ:SBPHNASDAQ:UMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$2.95-3.3%$6.30$2.81▼$485.37$2.31M5.59606,388 shs233,214 shsCLRBCellectar Biosciences$4.86-31.6%$8.79$4.36▼$94.50$12.87M0.51141,122 shs859,939 shsPRPHProPhase Labs$0.38-2.4%$0.34$0.22▼$4.03$16.25M-0.413.13 million shs673,754 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/AUMRXCogent Biosciences$7.22+0.6%$10.50$0.29▼$3.72$306.63M3.931.22 million shs2.32 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics-3.28%-14.74%-37.89%-89.31%-99.97%CLRBCellectar Biosciences-31.65%-49.90%-35.46%-46.38%-93.65%PRPHProPhase Labs-2.38%+9.14%+0.82%-2.05%-90.59%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%UMRXCogent Biosciences+1.13%-1.10%+31.99%+24.01%-19.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics2.6983 of 5 stars3.53.00.00.02.70.01.3CLRBCellectar Biosciences3.1031 of 5 stars3.25.00.00.03.00.01.3PRPHProPhase Labs0.9154 of 5 stars0.05.00.00.02.10.00.6SBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.007,424,984.75% UpsideCLRBCellectar Biosciences 2.33Hold$375.007,616.05% UpsidePRPHProPhase Labs 0.00N/AN/AN/ASBPHSpring Bank Pharmaceuticals 0.00N/AN/AN/AUMRXCogent Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APVO, PRPH, UMRX, CLRB, and SBPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.72N/AN/A$65.21 per share0.05CLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/APRPHProPhase Labs$6.77M2.34N/AN/A$0.25 per share1.53SBPHSpring Bank PharmaceuticalsN/AN/AN/AN/A$2.16 per shareN/AUMRXCogent Biosciences$22.50M13.63N/AN/A$1.04 per share6.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)CLRBCellectar Biosciences-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/11/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)SBPHSpring Bank Pharmaceuticals-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/AUMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/ALatest APVO, PRPH, UMRX, CLRB, and SBPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A5/13/2025Q1 2025CLRBCellectar Biosciences-$5.10-$3.90+$1.20-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A0.670.67CLRBCellectar BiosciencesN/A2.472.47PRPHProPhase Labs0.301.030.98SBPHSpring Bank PharmaceuticalsN/A5.115.11UMRXCogent Biosciences0.182.902.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CLRBCellectar Biosciences16.41%PRPHProPhase Labs9.45%SBPHSpring Bank Pharmaceuticals17.17%UMRXCogent Biosciences26.39%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.12%CLRBCellectar Biosciences5.04%PRPHProPhase Labs9.60%SBPHSpring Bank Pharmaceuticals12.70%UMRXCogent Biosciences31.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics50760,000755,000Not OptionableCLRBCellectar Biosciences101.81 million1.72 millionOptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableSBPHSpring Bank Pharmaceuticals3017.27 millionN/ANot OptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableAPVO, PRPH, UMRX, CLRB, and SBPH HeadlinesRecent News About These CompaniesCogent Biosciences Secures $400 Million Debt Financing Facility to Support Growth and Upcoming Bezuclastinib LaunchJune 11, 2025 | quiverquant.comQWhy Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy NowMay 13, 2025 | insidermonkey.comCogent Biosciences Advances with Promising Clinical TrialsMay 6, 2025 | tipranks.comIs Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?May 5, 2025 | insidermonkey.comCogent Biosciences (COGT): Among the Most Promising Penny Stocks According to AnalystsApril 20, 2025 | insidermonkey.comIs Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 17, 2025 | msn.comCogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comIs Cogent Biosciences, Inc. (COGT) a Best Biotech Stock According to Billionaires?March 17, 2025 | insidermonkey.comCogent Biosciences (COGT) Initiated with a Buy at ScotiabankMarch 10, 2025 | markets.businessinsider.comCogent Biosciences initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comCogent Biosciences reports Q4 net loss $67.9M vs. $54.4M last yearFebruary 25, 2025 | markets.businessinsider.comCogent Biosciences sees cash runway into late 2026February 25, 2025 | markets.businessinsider.comCogent Biosciences Inc (COGT) Stock: More Resilient Than It AppearsJanuary 24, 2025 | bovnews.comBCogent Biosciences exec buys $332K in common stockJanuary 16, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Cogent Biosciences (COGT)January 14, 2025 | markets.businessinsider.comCogent Biosciences price target lowered to $14 from $17 at H.C. WainwrightJanuary 14, 2025 | markets.businessinsider.comCogent Biosciences (COGT) Gets a Buy from J.P. MorganDecember 19, 2024 | markets.businessinsider.comCogent Biosciences Reports Promising APEX Phase 2 Trial Results for Bezuclastinib in Advanced Systemic Mastocytosis at ASH 2024December 8, 2024 | quiverquant.comQCogent Biosciences price target raised to $21 from $19 at JPMorganNovember 15, 2024 | markets.businessinsider.comCogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 12, 2024 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, PRPH, UMRX, CLRB, and SBPH Company DescriptionsAptevo Therapeutics NASDAQ:APVO$2.95 -0.10 (-3.28%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$2.94 -0.01 (-0.34%) As of 07/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Cellectar Biosciences NASDAQ:CLRB$4.86 -2.25 (-31.65%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$4.82 -0.04 (-0.80%) As of 07/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.ProPhase Labs NASDAQ:PRPH$0.38 -0.01 (-2.38%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$0.39 +0.01 (+1.57%) As of 07/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Spring Bank Pharmaceuticals NASDAQ:SBPHSpring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.Cogent Biosciences NASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
